Short answer: Amycretin is Novo Nordisk's investigational single-molecule GLP-1 and amylin receptor agonist, developed in both injectable and oral formats. Early research reported roughly 22% body-weight reduction at 36 weeks (injectable) and up to about 13.1% at 12 weeks (oral). Unlike CagriSema's two-molecule combo, amycretin targets both pathways in one molecule. It is investigational, not approved, and supplied here research use only.
As obesity research moves beyond first-generation GLP-1 therapies, several next-generation candidates are being developed to target multiple biological pathways simultaneously. One of the most closely watched programs is Amycretin, an investigational compound from Novo Nordisk that combines GLP-1 receptor activity with amylin receptor activation.
Amycretin has attracted significant interest because it is being developed in both injectable and oral formulations. Early clinical research has demonstrated substantial body-weight reductions, leading many researchers to view Amycretin as a potential successor to current incretin-based approaches. This article reviews the science behind Amycretin, available clinical data, development status, and the role amylin biology may play in the future of obesity research.
Plain-English summary. Amycretin is a research-stage molecule, not a medicine you can buy or use. Everything below describes published preclinical and clinical-trial findings for laboratory and educational context. New-U supplies research-use-only material and does not provide dosing, medical, or human-use guidance.
Amycretin is an investigational peptide-based therapy developed by Novo Nordisk. The compound combines:
Researchers designed Amycretin to leverage the complementary effects of two biological systems involved in satiety, food intake, and energy balance. Unlike CagriSema, which combines two separate molecules, Amycretin was designed as a single molecular entity capable of targeting both pathways.
GLP-1 is an incretin hormone involved in appetite regulation, glucose homeostasis, gastric emptying, and satiety signalling. The success of GLP-1 therapies transformed obesity and metabolic-disease research over the last decade.
Amylin is a hormone released alongside insulin. Researchers believe amylin influences meal termination, satiety responses, food intake, and energy regulation. Interest in amylin-based therapies has increased significantly as developers search for approaches beyond GLP-1 alone.
The obesity field increasingly views multi-pathway therapies as a possible route toward greater efficacy. Researchers believe combining GLP-1 and amylin biology may enhance satiety signalling, improve appetite control, influence multiple metabolic pathways simultaneously, and produce additive effects beyond single-pathway approaches. Whether these theoretical advantages translate into long-term clinical benefits remains under investigation.
Early clinical research involving injectable Amycretin produced some of the most discussed findings in the obesity-development landscape. Reported data demonstrated approximately:
These findings positioned Amycretin among the leading investigational candidates currently in development.
One of the most distinctive aspects of the Amycretin program is the parallel development of an oral formulation. Early research reported up to approximately 13.1% body-weight reduction at 12 weeks, encouraging dose-response trends, and continued development planning. Researchers are paying close attention to oral incretin development because successful oral therapies could expand accessibility and convenience.
Amycretin and CagriSema are frequently compared because both involve amylin biology. Key differences include:
Researchers continue to monitor whether either approach ultimately demonstrates superior long-term outcomes.
Amycretin remains in clinical development. Future milestones may include expanded late-stage studies, larger obesity populations, long-term safety evaluation, and potential regulatory submissions. The timeline remains dependent on ongoing clinical outcomes.
Amycretin represents one of the most intriguing next-generation obesity-research candidates currently under development. By combining GLP-1 and amylin biology within a single molecule and pursuing both injectable and oral formulations, Novo Nordisk is exploring multiple pathways that may shape the future of metabolic research. As clinical development progresses, Amycretin is likely to remain a central focus within the rapidly evolving obesity-therapy landscape.
What is amycretin?
Novo Nordisk's investigational single-molecule GLP-1 and amylin receptor agonist, in oral and injectable development. Investigational, not approved; research use only.
How is it different from CagriSema?
CagriSema combines two molecules (semaglutide + cagrilintide); amycretin targets both pathways in one molecule, at an earlier development stage.
How much weight loss did it show?
Early data reported ~22% at 36 weeks (injectable) and up to ~13.1% at 12 weeks (oral).
Is amycretin FDA approved?
No - it remains in clinical development. Material supplied as amycretin is research use only, not for human consumption.
Research use disclaimer. This article is provided for scientific and educational discussion purposes only. Amycretin remains an investigational therapy. No medical advice, treatment recommendations, dosing information, or human-use instructions are provided.
New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.
Browse the catalog